Informatics firm Humedica raises $20M

Humedica, which offers clinical informatics to life sciences companies and other healthcare customers, has raised $20 million in what appears to be a second round of equity financing, according to an SEC filing.

A spokesman for the Boston-based company said that he was unable to comment on the financing. The regulatory filing doesn't identify the investors in the new round, but the firm's previous backers from Bain Capital Ventures, General Catalyst Partners, healthcare investment bank Leerink Swann and North Bridge Venture Partners are all represented on its board of directors. In 2008, Humedica raised $30 million in a round of venture capital. Also, the firm's board features Paul Bleicher, the former chief executive and chairman of Phase Forward, a provider of electronic data capture software and other applications for firms involved in clinical trials. Tech giant Oracle ($ORCL) scooped up Phase Forward last in a buyout valued at $685 million.

Humedica appears to be developing its clinical informatics software for at least three stakeholders in healthcare: hospitals, outpatient clinics and life sciences companies (the third one of the three being of most interest to us here at FierceBiotech IT.) For life sciences firms, Humedica says that its clinical informatics software can be used to better understand how doctors prescribe medicines or other products for certain patients, measure the benefits of such products, and pinpoint new market opportunities. Of course, the firm's system is designed to protect the personal identities of individual patients to comply with HIPAA. 

It's not clear how many life sciences companies are using Humedica's informatics product, given that most of the firm's headlines to date have been related to its work in the healthcare provider arena. But FierceBiotech IT is seeking interviews with executives such as Steve Davis, the firm's vice president and general manager of life sciences, for more details about the company's offerings for product-focused outfits like biotech and drug companies.

- read the report from the Boston Business Journal
- here's the SEC filing on the financing